Sign in

Myelodysplastic syndromes

Current status: Treatable, not yet curable

A group of blood cancers in which the bone marrow makes blood cells that do not grow into healthy ones. Too few healthy blood cells can lead to infection, anaemia or easy bleeding. Treatment ranges from blood transfusions and medicines to strong chemotherapy with a stem cell transplant, which can cure some people. It is rare and more likely after age 60, or after chemotherapy or radiotherapy for another cancer.

Read more about myelodysplastic syndromes
Where research stands todayUpdated 18 Nov 2026

Trial-stage treatments and research studies you can joinOpen trials for referral

Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.

Filters

Country
City
Distance is calculated in your browser. Your city is not sent to us.
Type
Get notified of new trialsAustralia, all cities, all phases
Your ageShows only trials that take people your age.
Phase
  1. Trial-stage treatmentPhase 3Taking people
    Tests elritercept in adults with myelodysplastic syndromes needing regular blood transfusions

    Tests elritercept against placebo in adults with low-risk myelodysplastic syndromes needing transfusions.

    Adelaide, AustraliaAlso Box Hill, Douglas, Fitzroy, Garran, Melbourne, Parkville, SydneyAge 18+
  2. Trial-stage treatmentPhase 3Taking people
    Elritercept Compared With Epoetin Alfa for Anemia in Lower Risk Myelodysplastic Syndromes

    Compares elritercept with epoetin alfa for anemia in adults with myelodysplastic syndrome needing transfusions.

    Adelaide, AustraliaAlso Bedford Park, Clayton, Coffs Harbour, Fitzroy, Heidelberg, Perth, Richmond, Sydney, …Age 18+
  3. Trial-stage treatmentPhase 1
    Continued Treatment and Safety Monitoring for People With Certain Cancers

    Follows people with blood cancers and solid tumors who continue study drugs long term.

    Melbourne, AustraliaAlso Nedlands, RandwickAge 18+
  4. Trial-stage treatmentPhase 1Taking people
    Tests APL-4098 alone and with other drugs in adults with blood cancers

    Tests APL-4098, alone or with azacitidine, in adults with acute myeloid leukemia or MDS.

    Clayton, AustraliaAlso Fitzroy, Melbourne, Nedlands, PerthAge 18+
  5. Trial-stage treatmentPhase 1/2
    Tests AZD3632 alone or with other drugs in advanced blood cancers

    Tests the oral drug AZD3632 in adults with advanced leukemia or myelodysplastic syndromes.

    Fitzroy, AustraliaAlso PerthAge 16+
  6. Trial-stage treatmentPhase 1/2Taking people
    Tests DISC-0974 in adults with myelofibrosis or myelodysplastic syndrome and anemia

    Tests the drug DISC-0974 in adults with myelofibrosis or myelodysplastic syndrome and anemia.

    Nedlands, AustraliaAlso Saint Albans, Sydney, West PerthAge 18+
  7. Trial-stage treatmentPhase 2Taking people
    Tests elritercept for anemia in adults with lower-risk myelodysplastic syndromes

    Tests elritercept at different doses for anemia in adults with lower-risk MDS.

    Adelaide, AustraliaAlso Albury, Bedford Park, Box Hill, Douglas, Geelong, Heidelberg, Melbourne, Tweed Heads, …Age 18+
  8. Trial-stage treatmentPhase 3Taking people
    Tests lisaftoclax with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome

    Tests lisaftoclax plus azacitidine against placebo in adults with newly diagnosed higher-risk myelodysplastic syndrome.

    Blacktown, AustraliaAlso Cooloongup, Epping, Heidelberg, Kingswood, Liverpool, Melbourne, Perth, Richmond, …Age 18+
  9. Trial-stage treatmentPhase 2Taking people
    Tests bezuclastinib in adults with advanced systemic mastocytosis

    Tests bezuclastinib in adults with advanced systemic mastocytosis, a rare blood disease.

    Kingswood, AustraliaAlso SouthportAge 18+
  10. Trial-stage treatmentPhase 1/2Taking people
    Tests BGB-11417 alone or with azacitidine in myeloid blood cancers

    Tests BGB-11417, alone or with azacitidine, in adults with acute myeloid leukemia or MDS.

    Clayton, AustraliaAlso Concord, Fitzroy, Heidelberg, Kogarah, Melbourne, Murdoch, Nedlands, Orange, …Age 18+
  11. Trial-stage treatmentPhase 3Taking people
    Compares ivosidenib and azacitidine in people with IDH1-mutated myelodysplastic syndromes

    Compares two treatments in adults with myelodysplastic syndromes who have an IDH1 gene change.

    Adelaide, AustraliaAlso Clayton, Epping, Liverpool, Nedlands, WaratahAge 18+
  12. Trial-stage treatmentPhase 1Taking people
    Tests ICP-248 with azacitidine in leukemia and myelodysplastic syndromes

    Tests ICP-248 with azacitidine in adults with leukemia or myelodysplastic syndromes.

    Perth, AustraliaAlso SydneyAge 18+
  13. Trial-stage treatmentPhase 3Taking people
    Long-term safety of luspatercept in people from earlier luspatercept studies

    Continues luspatercept treatment and follow-up in adults with anemia-related blood disorders.

    Adelaide, AustraliaAlso Camperdown, Clayton, South BrisbaneAge 18+
  14. Trial-stage treatmentPhase 1/2Taking people
    Tests experimental drug EP0042 alone and with other cancer treatments

    Tests experimental drug EP0042 in adults with leukemia and related blood cancers.

    Perth, AustraliaAge 18+
  15. Trial-stage treatmentPhase 1Taking people
    Tests two oral drugs together in myelodysplastic syndromes and certain leukemias

    Tests decitabine/cedazuridine with defactinib in adults with myelodysplastic syndrome or leukemia.

    Sydney, AustraliaAlso WestmeadAge 18+
  16. Trial-stage treatmentPhase 1/2
    Tests tuspetinib in adults with relapsed or refractory acute myeloid leukemia

    Tests tuspetinib, alone or with other drugs, in adults with acute myeloid leukemia.

    Albury, AustraliaAlso Fitzroy, Herston, Nedlands, TownsvilleAge 18+
  17. Trial-stage treatmentPhase 1/2Taking people
    Testing bone marrow and blood in children with relapsed or hard-to-treat leukemia

    Examines bone marrow and blood samples from young people with leukemia that returned.

    Parkville, AustraliaAlso Perth, South Brisbane, WestmeadUp to age 22

Search the publications

The results open on the publications page in a new tab, so this page stays as it is.

Lists with this disease filtered

Where treatment stands

Some patients can be cured with strong chemotherapy and a stem cell transplant from a donor. For others, treatment may slow the disease from getting worse.

In the EU, imetelstat and efbemalenograstim alfa were first approved in 2025 and 2024, not always for this disease.

Approved: 13

Officially approved for this disease in the EU, the US, Switzerland or France.

Human testing stage: 11

Being tested in people. Many treatments at this stage are never approved.

Animal testing stage: 3

Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.

Support organisations

Patient organisations and helplines in Australia, for you and your family.

Myelodysplastic syndromes organisations in Australia

  • Cancer Council Australia

    Australia's peak independent cancer charity giving evidence-based information on prevention, research, treatment and support for people affected by cancer.

  • Leukaemia Foundation

    Australian charity for people with leukaemia, lymphoma, myeloma, MDS and related blood cancers: health and support services, research funding and advocacy.

General support in Australia

  • Lifeline Australia

    Lifeline Australia: national charity providing all Australians with 24-hour crisis support and suicide prevention services.

  • healthdirect Australia

    healthdirect, the Australian Government-funded service providing trusted health information and advice online and by phone (1800 022 222).

International organisations

  • Aplastic Anemia and MDS International Foundation

    Foundation supporting patients and families with aplastic anemia, MDS and related bone marrow failure diseases.

  • DKMS

    Finds blood stem cell donors worldwide so that people with blood cancer can have a transplant.

  • MDS Foundation

    US-based global nonprofit supporting patients with MDS and related diseases such as AML, their families and providers, with education, resources and support.

Frontlight Community

Myelodysplastic syndromes community in Australia

People living with myelodysplastic syndromes and those close to them share what they went through. Posts are not medical advice: ask your doctor about your own treatment.

Offer tissue or data

There are three ways to help research move faster.

Give tissue or bloodA biobank stores your sample so many research teams can use it.See open programmes
Share your health dataA patient registry collects your health data, without your name, for research.How to join
Take part as a healthy volunteerStudies also need people without the disease, for comparison. Family and friends can help.Volunteer

Approved treatments

17 medicines are approved for myelodysplastic syndromes in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.

Checked on 18 Nov 2026 in the official lists of the US (FDA), the EU (European Commission and EMA) and Switzerland (Swissmedic), which we read every day. The lists of Japan (PMDA, approvals since April 2004), France (ANSM, medicines approved in France only) and Taiwan (TFDA) were checked on 11 Nov 2026. For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. The French ratings are the opinions of the HAS Transparency Committee, from the French public medicines database (base de données publique des médicaments, newest opinion 10 Dec 2025). 6 uncertain matches are left out. Other countries' own approvals were not checked.

“Miracle cure” fact checker

Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.

What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.

Before you pay for anything, ask three things

  1. Is there a published study in people?
  2. Can I have the full price in writing?
  3. What does my doctor say?

About myelodysplastic syndromes

Sources: NCI PDQ, MedlinePlus, The Lancet Oncology

A group of blood cancers in which the bone marrow makes blood cells that do not grow into healthy ones. Too few healthy blood cells can lead to infection, anaemia or easy bleeding. Treatment ranges from blood transfusions and medicines to strong chemotherapy with a stem cell transplant, which can cure some people. It is rare and more likely after age 60, or after chemotherapy or radiotherapy for another cancer.

What is it?

Myelodysplastic syndromes (MDS) are a group of blood cancers. Normally, stem cells in the bone marrow grow into healthy red cells, white cells and platelets. In MDS many of them do not mature and die in the marrow. This leaves too few healthy blood cells, which can lead to anaemia (too few red cells), infections and bleeding.

MDS is rare and mostly affects older people: half are about 70 or older when they find out. In most people the cause is not known. The risk is higher after chemotherapy or radiotherapy for another cancer, and after contact with tobacco smoke, some chemicals (such as benzene, pesticides or fertilisers) or heavy metals such as lead and mercury.

The first signs

MDS often causes no early signs and is sometimes found by a routine blood test.

  • feeling weak or tired;
  • shortness of breath;
  • skin that is paler than usual;
  • bruising or bleeding easily, or tiny spots under the skin caused by bleeding;
  • fever or infections that keep coming back.

How doctors find out

Blood tests count the red blood cells, white blood cells and platelets. A bone marrow test takes a small sample of marrow with a needle, and a lab checks it for abnormal cells and chromosome changes. Some of these tests, such as checking the chromosomes, help plan treatment.

Current treatment

Treatment depends on several factors. It can include transfusions, medicines that help make red blood cells, and antibiotics for symptoms; lenalidomide or azacitidine and decitabine for some people; and chemotherapy with a donor stem cell transplant for certain patients.

Will it get worse?

Prognosis (chance of recovery) and treatment options depend on certain factors. How it goes depends on how many immature cells (blasts) are in the marrow, how many kinds of blood cells are low, certain chromosome changes, whether it followed earlier cancer treatment, and your age and general health. Some types of MDS can turn into acute myeloid leukaemia (AML).

Medicines: what helps, and what to watch for

Supportive care eases the problems caused by the disease. It can include red blood cell or platelet transfusions, medicines that help the body make more red blood cells, and antibiotics to fight infection. Azacitidine or decitabine can slow the change to AML. Lenalidomide helps some people with a certain chromosome change (del(5q)) need fewer transfusions. People at high risk of AML may get the same chemotherapy as for AML.

Good to know:

  • Many transfusions can build up too much iron in the body and harm organs; medicines can remove the extra iron;
  • You can join a clinical trial before, during or after treatment, and some trials take only people who have not started treatment.

A transplant, for some people

Some people can be cured with strong chemotherapy followed by a stem cell transplant from a donor, which gives them healthy blood-forming cells. It may not work as well when MDS was caused by earlier cancer treatment.

Is there a cure?

For some people, yes: strong chemotherapy with a donor stem cell transplant can cure certain patients. There is no standard treatment when MDS comes back or stops responding. Clinical trials are testing new treatments.

See the 397 trials you can join

Median survival

About 2 years with azacitidine, in higher-risk MDS

Measured in: Higher-risk myelodysplastic syndromes: a phase III trial of azacitidine against conventional care (358 patients)

The figures behind it

Phase III trial in higher-risk myelodysplastic syndromes (358 patients): median overall survival 24.5 months with azacitidine vs 15.0 months with conventional care regimens. Lower-risk MDS is not part of this figure.